• ILLUMENATE Shows Favorable Outcomes at 4 Years with Stellarex Drug-Coated Balloon

    At 4 years, the Stellarex paclitaxel drug-coated balloon (DCB) demonstrated favorable long-term safety and efficacy outcomes supporting its use in treating femoropopliteal lesions, according to study results presented Sunday at the TCT Connect virtual conference.

    Previous studies have described the short-term safety of paclitaxel-coated balloons; however, long-term data are lacking. The ILLUMENATE (Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon) Global trial was a prospective, single-arm, multicenter study designed to evaluate the Stellarex DCB (Royal Philips).

    Included were 371 patients with Rutherford Clinical Classification (RCC) of 2-4 being treated for superficial femoral artery (SFA) or popliteal artery lesions. The primary outcome of interest was freedom from device- and procedure-related death through 30 days and freedom from target limb major amputation and clinically-driven target lesion revisualization (CD-TLR) through 12 months. The primary efficacy outcome was primary patency at 12 months.

    Andrew Holden, MD, of Auckland Hospital, New Zealand, presented the 4-year results from the ILLUMENATE Trial at TCT Connect on Sunday. Patients had a mean age of 68.2 years, and 73% were men. Of those included, 42.3% of patients had previous intervention of the lower limb. De novo lesions occurred in 94% of patients with a mean luminal area of 0.96 mm and 40.8% having severe disease. Procedural success was achieved in 97.6% of patients with a mean post-procedure stenosis was 24.7% with a minimal luminal diameter of 3.43mm.

    The primary patency rate at 12 months was 81.4. The CD-TLR rate at 1 year was 6.2%. The majority of patients  (90.3%) experienced improvements in their RCC (90.3%) and walking impairment questionnaire score (83.6%) at 12 months compared to baseline, according to previously published findings.

    Patients were followed out to 5 years post-procedure.

    At 4 years, the primary safety endpoint of device- or procedure-related death occurred in zero patients and CD-TLR occurred in 21.8% of patients. Major target limb amputation occurred in just three patients. All-cause mortality occurred in 8.1% (n=30) of patients at 4 years. In a subgroup analysis, there were no significant differences in these outcomes stratified by sex, lesion length or pre-existing diabetes.

    Holden concluded that these data support durable long-term outcomes with the Stellarex DCB in de novo and re-stenotic in peripheral arterial disease irrespective of gender or diabetes.

    The ILLUMENATE trial was sponsored by Philips Image Guided Therapy.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details